文献速递脊柱关节炎

古塞奇尤单抗(IL-23 p19亚单位单克隆抗体)治疗两年长期疗效与安全性:一项在生物制剂初治活动性银屑病关节炎患者中开展的III期随机双盲安慰剂对照研究

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2022-02-07

DISCOVER-2试验纳入739例生物制剂初治活动性银屑病关节炎患者,随机接受古塞奇尤单抗每4周或每8周方案,或安慰剂后交叉至古塞奇尤单抗。至第100周,各古塞奇尤单抗治疗组ACR20应答率68-76%、ACR50 48-56%、ACR70 30-36%,皮损完全清除(IGA=0)55-67%,附着点炎消退62-70%,指炎消退72-83%,疗效持续至2年。第112周安全性评估未见意外安全信号。

要点

  • 至第100周,古塞奇尤单抗治疗组ACR20应答率68-76%、ACR50 48-56%、ACR70 30-36%,疗效持续至2年。
  • 至第100周,IGA评分为0者55-67%,附着点炎消退62-70%,指炎消退72-83%。
  • 第52周至第100周Sharp/van der Heijde改良评分平均变化范围0.13-0.75,影像学进展低速率延续至第100周。

核心结论

  • 在生物制剂初治银屑病关节炎患者中,古塞奇尤单抗在多个疾病领域提供持久改善,2年内未见意外安全性发现。

研究设计与样本

  • III期、随机、双盲、安慰剂对照DISCOVER-2试验,纳入739例对既往非生物制剂治疗应答不佳的活动性银屑病关节炎患者(肿胀关节≥5个且压痛关节≥5个;C反应蛋白≥0.6 mg/dl)。
  • 患者随机接受古塞奇尤单抗100 mg每4周、古塞奇尤单抗100 mg第0周和第4周后每8周、或安慰剂(第24周起交叉至古塞奇尤单抗100 mg每4周)。
  • 临床数据缺失时按无应答/基线无变化填补,影像学数据采用观察值,临床与影像学数据总结至第100周,安全性评估持续至第112周。

主要发现

  • 739例随机并治疗患者中652例(88%)完成至第100周的治疗。
  • 至第100周,各古塞奇尤单抗治疗组(含安慰剂交叉组)ACR20应答率68-76%、ACR50 48-56%、ACR70 30-36%。
  • 至第100周,IGA评分为0者55-67%,附着点炎消退62-70%,指炎消退72-83%。
  • 第52周至第100周Sharp/van der Heijde改良评分平均变化范围0.13-0.75,提示早期观察到的低影像学进展速率延续至第100周。
  • 至第112周,731例古塞奇尤单抗治疗患者中8%(5.8/100患者年)发生严重不良事件,3%(1.9/100患者年)发生严重感染;发生1例死亡(道路交通事故)。

关键数值与推荐

  • ACR20应答率68-76%、ACR50应答率48-56%、ACR70应答率30-36%(第100周,各古塞奇尤单抗治疗组)。
  • IGA评分为0者55-67%、附着点炎消退62-70%、指炎消退72-83%(第100周,各古塞奇尤单抗治疗组)。
  • 第52周至第100周Sharp/van der Heijde改良评分平均变化0.13-0.75。
  • 严重不良事件8%(5.8/100患者年)、严重感染3%(1.9/100患者年)(至第112周,731例古塞奇尤单抗治疗患者)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess long-term efficacy and safety of guselkumab, an interleukin-23 p19 subunit (IL-23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III DISCOVER-2 trial. METHODS: In the DISCOVER-2 trial, patients with active PsA (≥5 swollen joints and ≥5 tender joints; C-reactive protein level ≥0.6 mg/dl) despite prior nonbiologic therapy were randomized to receive the following: guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0 and 4 and then every 8 weeks; or placebo with crossover to guselkumab 100 mg every 4 weeks, beginning at week 24. Efficacy assessments included American College of Rheumatology ≥20%/50%/70% improvement criteria (ACR20/50/70), Investigator's Global Assessment (IGA) of psoriasis score of 0 (indicating complete skin clearance), resolution of enthesitis (Leeds Enthesitis Index) and dactylitis (Dactylitis Severity Score), and changes in the Sharp/van der Heijde modified radiographic scores for PsA. Clinical data (imputed as no response/no change from baseline if missing) and observed radiographic data were summarized through week 100; safety assessments continued through week 112. RESULTS: Of the 739 randomized and treated patients, 652 (88%) completed treatment through week 100. Across groups of guselkumab-treated patients (including those in the placebo-guselkumab crossover group), the following findings at week 100 indicated that amelioration of arthritis signs/symptoms and extraarticular manifestations was durable through 2 years: ACR20 response (68-76%), ACR50 response (48-56%), ACR70 response (30-36%), IGA score of 0 (55-67%), enthesitis resolution (62-70%), and dactylitis resolution (72-83%). Mean changes in the Sharp/van der Heijde modified score for PsA from weeks 52 to week 100 (range 0.13-0.75) indicated that the low rates of radiographic progression observed among guselkumab-treated patients at earlier time points extended through week 100. Through week 112, 8% (5.8 per 100 patient-years) and 3% (1.9 per 100 patient-years) of the 731 guselkumab-treated patients had a serious adverse event or serious infection, respectively; 1 death occurred (road traffic accident). CONCLUSION: In biologic-naive PsA patients, guselkumab provided durable improvements in multiple disease domains with no unexpected safety findings through 2 years.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. McInnes IB, Rahman P, Gottlieb AB, et al. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis. Arthritis Rheumatol. 2022. PMID: 34719872. doi:10.1002/art.42010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。